Actively Recruiting
Hemodynamics in Chronic Hemodialysis Patients Undergoing Isolated Ultrafiltration Compared to Conventional Hemodialysis
Led by Medical University of Graz · Updated on 2025-03-04
32
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients with end stage kidney disease undergoing hemodialysis face a high risk of cardiovascular problems and complications such as intradialytic hypotension (IDH), which can cause damage to the heart, brain, gastrointestinal system, and dialysis access. This study explores whether isolated ultrafiltration (iso-UF), a technique suggested to improve blood flow stability during dialysis, offers benefits compared to conventional hemodialysis. The study is randomized and aims to clarify the effects of iso-UF on hemodynamics and patient outcomes using modern dialysis methods. Participants will receive two treatment sequences: one involving sequential hemodialysis where isolated ultrafiltration is performed first followed by standard hemodialysis for eight sessions, then switching to conventional hemodialysis for another eight sessions; the other sequence reverses this order. The study seeks to measure changes in peripheral resistance, osmolality, cardiac output, and cardiac power index, as well as to assess dialysis quality and duration. Throughout the study, researchers will monitor the total peripheral resistance index over up to eight weeks. Participants will undergo dialysis sessions according to the study schedule while being assessed for hemodynamic stability and dialysis effectiveness. The study includes detailed cardiovascular monitoring to understand how the different dialysis methods impact blood flow and patient health, with safety and dialysis quality closely followed during the trial.
CONDITIONS
Brief Title
Hemodynamics in Chronic Hemodialysis Patients Undergoing Isolated Ultrafiltration Compared to Conventional Hemodialysis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Written consent of the participant after being informed
- At least 18 years of age
- End stage kidney disease patient undergoing hemodialysis
- Dry weight stable for a minimum of one month
- Interdialytic weight gain of >2 liters in the short interdialytic interval
You will not qualify if you...
- No informed consent was obtained
- Patients with a pacemaker or implanted medical device that prevents compliance with study regulations
- Patients treated with hemodiafiltration
- Patients treated with medium cut-off membranes (Theranova, Baxter)
- Patients with recurrent severe hyperkalemia after the short interdialytic interval (K+ concentration > 6.0 mmol/L, requiring more than 2 hours of dialysis to ameliorate the post-dialytic shift from other compartments)
- Women of childbearing age not using contraception
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Approximately 8 weeks
Participants receive sequential hemodialysis first for 8 sessions and then switch to conventional hemodialysis for another 8 sessions, or vice versa, to assess differences in hemodynamic stability.
16 dialysis sessions in total
Trial Site Locations
Total: 1 location
1
Medical University of Graz
Graz, Austria
Actively Recruiting
Research Team
A
Alexander H Kirsch
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here